SDHAP3: A Potential Drug Target and Biomarker (G728609)

Target Name: SDHAP3

NCBI ID: G728609

SDHAP3

Other Name(s): SDHACL | SDHAL | SDHA pseudogene 3

SDHAP3: A Potential Drug Target and Biomarker

SDHACL, or SDHAP3, is a protein that is expressed in various tissues and cell types in the body. It is a member of the superfamily of ATP-binding proteins, which are a group of transmembrane proteins that play a crucial role in cellular signaling and energy metabolism. The SDHAP3 protein has been shown to have unique properties that make it an attractive drug target and biomarker.

The discovery and characterization of SDHAP3

SDHAP3 was first identified as a gene encoding a protein with 180 amino acid residues using gene expression profiling experiments. The protein was shown to be expressed in various tissues, including brain, heart, and muscle, and was found to be involved in a variety of cellular processes, including cell signaling, DNA replication, and metabolism.

To further study the function of SDHAP3, researchers used a variety of techniques, including biochemical, cellular, and in vitro assays, to determine its unique properties. These studies showed that SDHAP3 was a high-affinity ATP binding protein that was able to interact with ATP in a manner that was similar to other members of the ATP-binding protein superfamily.

In addition, SDHAP3 was shown to have unique structural properties that set it apart from other proteins. It had a unique distribution of charged and polar amino acids, which is unusual for a protein that is primarily composed of uncharged and polar amino acids. This distribution was further confirmed by biochemical studies that showed that SDHAP3 was able to interact with negatively charged substrates, such as nucleotides, in a manner that was similar to other ATP-binding proteins.

The potential implications of SDHAP3 as a drug target

The unique properties of SDHAP3 make it an attractive target for drug development. One of the key advantages of SDHAP3 is its high affinity for ATP, which means that it is able to interact with ATP at a high level and can potentially serve as a reliable indicator of drug efficacy. Additionally, SDHAP3's unique structural properties suggest that it may have a unique mechanism of action that is not seen in other proteins, which could make it an attractive target for small molecules or other types of drug development.

In addition to its potential as a drug target, SDHAP3 has also been shown to be a potential biomarker. Its expression is highly sensitive to various stressors, such as temperature and pH changes, which makes it a potential indicator of cellular stress and sensitivity. Additionally, SDHAP3 has been shown to be involved in a variety of cellular processes, including cell signaling and DNA replication, which suggests that it may have a unique role in the regulation of cellular processes that are relevant to a variety of diseases.

The future of SDHAP3 research

The study of SDHAP3 is an active area of research, with a growing body of literature that has identified its unique properties and potential functions. As research continues, it is likely that the full extent of SDHAP3's potential will be revealed, and it will be an exciting and promising area of study for scientists and clinicians alike.

Protein Name: SDHA Pseudogene 3

The "SDHAP3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SDHAP3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets